Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-754807 · 5 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| BMS-754807 + Metformin | EXPERIMENTAL | - |
| BMS-754807 | EXPERIMENTAL | - |
| A | EXPERIMENTAL | Combination |
| Sequential allocation of patients in two dosing schedules | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-754807 (IGR-IR/IR Inhibitor) | DRUG | Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17 |
| Metformin | DRUG | Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily |
| BMS-754807 | DRUG | Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response |
| trastuzumab (Herceptin®) | DRUG | IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop |
| Paclitaxel | DRUG | Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request |
| Carboplatin | DRUG | Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request |
Inclusion Criteria: * Healthy male and female subjects ages 18 to 55 determined with no clinically significant deviation from normal medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory * Women who are not of childbearing potential Exclusion Criteria: * Eviden...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-754807 is an investigational small molecule being studied in oncology. It has been evaluated in clinical trials for breast cancer, advanced solid tumors, metastatic solid tumors, and neoplasms, as well as in healthy volunteers for glucose-related assessments. It is not approved and remains in clinical development.
BMS-754807 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company has sponsored multiple Phase 1 clinical trials of this investigational oncology drug.
BMS-754807 is in Phase 1 clinical development. All four completed trials were Phase 1 studies. It is an investigational drug and has not been approved by regulatory authorities. No active trials are currently listed for this asset.
BMS-754807 has completed four Phase 1 trials: NCT00788333 combining it with Herceptin in HER2-positive breast cancer, NCT00793897 combining it with paclitaxel and carboplatin in advanced solid tumors, NCT00898716 a multiple ascending dose study in Japanese patients with solid tumors, and NCT01525823 assessing blood glucose changes in healthy volunteers.
No, BMS-754807 is not the same as Herceptin. BMS-754807 is an investigational small molecule developed by Bristol-Myers Squibb, while Herceptin is a separate drug. They were studied in combination in a Phase 1 trial for HER2-positive breast cancer, but they are distinct agents.